MA41633A - Composés amide en tant qu'agonistes du récepteur 5-ht4 - Google Patents

Composés amide en tant qu'agonistes du récepteur 5-ht4

Info

Publication number
MA41633A
MA41633A MA41633A MA41633A MA41633A MA 41633 A MA41633 A MA 41633A MA 41633 A MA41633 A MA 41633A MA 41633 A MA41633 A MA 41633A MA 41633 A MA41633 A MA 41633A
Authority
MA
Morocco
Prior art keywords
compounds
agonists
receptor
sub
amid compounds
Prior art date
Application number
MA41633A
Other languages
English (en)
Other versions
MA41633B1 (fr
Inventor
Gopinadh Bhyrapuneni
Narsimha Bogaraju
Venkateswarlu Jasti
Pradeep Jayarajan
Abdul Rasheed Mohammed
Ramakrishna Nirogi
Sangram Keshari Saraf
Anil Karbhari Shinde
Ramkumar Subramanian
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of MA41633A publication Critical patent/MA41633A/fr
Publication of MA41633B1 publication Critical patent/MA41633B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

<!--startfragment-->la présente invention concerne des composés de formule (i), y compris des stéréoisomères et des sels pharmaceutiquement acceptables de ceux-ci. Cette invention concerne en outre des procédés de fabrication de ces composés et de compositions pharmaceutiques comprenant ces composés. Les composés de cette invention sont utiles dans le traitement de différents troubles liés à des agonistes du récepteur de 5-hydroxytryptamine 4 (5-ht<sub>4</sub>).<img alt="front page image" src="https://patentscope.Wipo.Int/search/docs2/pct/wo2016128990/pic/o77ibndw5syuptcyihxllvudfmze3r1pakep7vxt1wqaedmzaq4begmslchvbzgb_-wdydplun9d2ggdvhwyztjd19b5aurw5na85try4k8swryypznlaabi2yxvwu9cc-ag-gepuw6xugh3s-pvwamzg9ydyro9ypaftawrfnw?Docid=id00000034559781&psauth=v5dpxr6mniqdagukduehpxl_zldlk4qkwyeroo99k68" /><!--endfragment-->
MA41633A 2015-02-13 2016-01-07 Composés amide en tant qu'agonistes du récepteur 5-ht4 MA41633B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN709CH2015 2015-02-13
PCT/IN2016/000008 WO2016128990A1 (fr) 2015-02-13 2016-01-07 Composés d'amide en tant qu'agonistes du récepteur de 5-ht4

Publications (2)

Publication Number Publication Date
MA41633A true MA41633A (fr) 2019-05-15
MA41633B1 MA41633B1 (fr) 2019-07-31

Family

ID=55588327

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41633A MA41633B1 (fr) 2015-02-13 2016-01-07 Composés amide en tant qu'agonistes du récepteur 5-ht4

Country Status (30)

Country Link
US (1) US9957257B2 (fr)
EP (1) EP3265459B1 (fr)
JP (1) JP6487564B2 (fr)
KR (1) KR101966576B1 (fr)
CN (1) CN107406434B (fr)
AU (1) AU2016217461B2 (fr)
BR (1) BR112017017275A2 (fr)
CA (1) CA2975973C (fr)
CY (1) CY1121898T1 (fr)
DK (1) DK3265459T3 (fr)
EA (1) EA034618B1 (fr)
ES (1) ES2734734T3 (fr)
HR (1) HRP20191179T1 (fr)
HU (1) HUE045667T2 (fr)
IL (1) IL253848B (fr)
LT (1) LT3265459T (fr)
MA (1) MA41633B1 (fr)
MD (1) MD3265459T2 (fr)
ME (1) ME03430B (fr)
MX (1) MX368214B (fr)
NZ (1) NZ734400A (fr)
PL (1) PL3265459T3 (fr)
PT (1) PT3265459T (fr)
RS (1) RS59066B1 (fr)
SG (1) SG11201706501VA (fr)
SI (1) SI3265459T1 (fr)
SM (1) SMT201900398T1 (fr)
TR (1) TR201909997T4 (fr)
WO (1) WO2016128990A1 (fr)
ZA (1) ZA201705292B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2619829T3 (es) 2011-11-18 2017-06-27 Heptares Therapeutics Limited Agonistas del receptor muscarínico M1
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
GB201709652D0 (en) * 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CN110818661B (zh) * 2019-12-02 2021-08-06 上海再启生物技术有限公司 5-ht4受体激动剂的关键中间体4-氨基-5-卤苯并呋喃-7-羧酸的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2338882T3 (es) 2003-11-24 2010-05-13 Pfizer, Inc. Compuestos de acido quinolona-carboxilico que tienen actividad agonista del receptor 5-ht4.
WO2005092882A1 (fr) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. Derives de 4-amino-5-halogeno-benzamide utiles comme agonistes du recepteur 5-ht4 dans le traitement des troubles gastro-intestinaux, du systeme nerveux central, neurologiques et cardio-vasculaires
US8816090B2 (en) 2005-02-25 2014-08-26 Pfizer Inc. Benzisoxazole derivatives
WO2007010390A1 (fr) 2005-07-22 2007-01-25 Pfizer Japan Inc. Derives d’ndazolecarboxamides en tant qu'agonistes des recepteurs 5ht4
AR056729A1 (es) * 2005-10-28 2007-10-17 Glaxo Group Ltd Compuesto de benzofurano carboxamida, composicion farmaceutica que lo comprende su uso para preparar un medicamento y procesos para su preparcion
GB0525661D0 (en) * 2005-12-16 2006-01-25 Glaxo Group Ltd Novel compounds
GB0603550D0 (en) 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds
CN107260736A (zh) * 2010-02-12 2017-10-20 株式会社AskAt 用于治疗痴呆的5‑ht4受体激动剂
KR20120123089A (ko) 2010-02-16 2012-11-07 화이자 인코포레이티드 5-HT₄ 수용체의 부분 효능제인 (R)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조[d]이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2H-피란-4-올
DK2758394T3 (en) * 2011-09-19 2015-04-20 Suven Life Sciences Ltd HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS
DK2976337T3 (en) * 2013-03-20 2018-07-16 Suven Life Sciences Ltd 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
EA029951B1 (ru) * 2013-12-16 2018-06-29 Сувен Лайф Сайенсиз Лимитед Соединения индазола в качестве агонистов 5-ht-рецептора

Also Published As

Publication number Publication date
TR201909997T4 (tr) 2019-07-22
PT3265459T (pt) 2019-07-17
HRP20191179T1 (hr) 2019-10-04
CN107406434A (zh) 2017-11-28
BR112017017275A2 (pt) 2018-04-17
EA034618B1 (ru) 2020-02-27
MX2017010348A (es) 2018-06-07
EP3265459A1 (fr) 2018-01-10
IL253848B (en) 2018-01-31
AU2016217461B2 (en) 2018-07-05
CN107406434B (zh) 2020-09-11
JP6487564B2 (ja) 2019-03-20
CA2975973C (fr) 2019-07-16
DK3265459T3 (da) 2019-07-15
ME03430B (fr) 2020-01-20
CA2975973A1 (fr) 2016-08-18
KR20170117167A (ko) 2017-10-20
SG11201706501VA (en) 2017-09-28
RS59066B1 (sr) 2019-09-30
AU2016217461A1 (en) 2017-09-14
MX368214B (es) 2019-09-24
US9957257B2 (en) 2018-05-01
ES2734734T3 (es) 2019-12-11
KR101966576B1 (ko) 2019-04-05
IL253848A0 (en) 2017-09-28
MD3265459T2 (ro) 2019-09-30
SI3265459T1 (sl) 2019-09-30
JP2018509396A (ja) 2018-04-05
CY1121898T1 (el) 2020-10-14
WO2016128990A1 (fr) 2016-08-18
SMT201900398T1 (it) 2019-09-09
US20180051011A1 (en) 2018-02-22
HUE045667T2 (hu) 2020-01-28
EP3265459B1 (fr) 2019-05-15
LT3265459T (lt) 2019-08-26
PL3265459T3 (pl) 2019-09-30
ZA201705292B (en) 2019-06-26
NZ734400A (en) 2018-03-23
MA41633B1 (fr) 2019-07-31
EA201791829A1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
MA41633B1 (fr) Composés amide en tant qu&#39;agonistes du récepteur 5-ht4
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu&#39;inhibiteurs de kinases dépendantes des cyclines
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA44674A (fr) Inhibiteurs de bromodomaine
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MA43169B1 (fr) Composés héterocycliques en tant qu&#39; inhibiteurs pi3k-gamma
MA38175A1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA46357B1 (fr) Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA33450B1 (fr) Dérivés d&#39;oxazine et leur utilisation en tant qu&#39;inhibiteurs de bace pour le traitement de troubles neurologiques
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA38240A1 (fr) Nouveaux composes dimeres substitues antagonistes de l&#39;iap utiles pour le traitement du cancer, de preference des tumeurs solides
MA54386B1 (fr) Modulateurs de trex1
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
JOP20250025A1 (ar) صور بلورية وأملاح من ناهض مستقبل مسكاريني
EA202092146A1 (ru) Производные пиразотетрагидроизохинолина в качестве положительных модуляторов допаминового d1 рецептора
MA49127B1 (fr) Dérivés d&#39;indole n-substitués
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA50069B1 (fr) Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu&#39;inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu&#39;antagonistes des récepteurs des orexines